🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

"The patent ensures strong protection for GmPcides, which is crucial in our industry, and represents a significant step toward making our compounds available to patients in need of effective treatment for drug-resistant bacteria," says Markus Thor. nordiclifescience.org/quretech-bio-g…

"For his ability to combine scientific excellence with strategic execution over two decades has been crucial in realizing Camurus full development and commercial potential, and creating long-term value for both patients and shareholders," writes the jury. nordiclifescience.org/fredrik-tiberg…

Understanding the science is one thing, but being able to manufacture T-cell therapies at scale is a different matter. NLS visited Anocca in Södertälje to learn more! nordiclifescience.org/scaling-the-ne…

"The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline," says Martin Holst Lange Novo Nordisk nordiclifescience.org/novo-nordisk-a…

"This approach allows us to attract specialist investors who typically do not invest in the public market, while current shareholders in Toleranzia retain a liquid share in Flerie," says Ted Fjallman CEO of #Flerie Toleranzia AB nordiclifescience.org/flerie-and-tol…

This issue of The Altascientist from Altasciences LA explores the current and future of GLP-1 receptor agonists, including their expanding applications in treating various health conditions. nordiclifescience.org/ad/discover-th…

"This partnership provides an important confirmation of our market potential and provides important support for our project," says Stian Kildal, CEO OncoZenge AB nordiclifescience.org/oncozenge-in-a…

"Each heart contraction is caused by an influx of calcium into the heart cell. Our agents work by increasing the sensitivity of the heart muscle to this calcium, so that the contraction becomes stronger." – Patrik Strömberg. nordiclifescience.org/global-health-…

"Our study shows how different cell types arise from stem cells in the embryo and how they are organized to create important structures in the brain," says Emma Andersson Karolinska Institutet nordiclifescience.org/a-family-tree-…

"By separating the targeting phase from the therapeutic phase, we create new conditions for developing more precise and effective cancer treatments," says Marika Nestor, CEO, Akiram Therapeutics. nordiclifescience.org/akiram-therape…

"Production costs will increase even for American pharmaceutical companies, as the tariffs will disrupt supply chains for critical raw materials, packaging, and consumables needed to manufacture medicines," says Jessica Martinsson SwedenBIO nordiclifescience.org/no-us-market-t…

Even though many have tried and few succeeded in the quest to find viable treatments for neurodegenerative diseases, Nordic drug developers continue to take different approaches to crack the riddle. Alzinova Polku Therapeutics nordiclifescience.org/global-health-…

TIRmed Pharma has raised financing in a funding round led by Sciety and Sciety Venture Partners. nordiclifescience.org/tirmed-pharma-…

The map is designed to provide patients and healthcare professionals with easy access to comprehensive, real-time information about clinical trials conducted in their area, increasing access to clinical research in the EU. nordiclifescience.org/new-clinical-t…

This is the first therapy targeting an underlying cause of Alzheimer’s disease (AD) to be granted an MA in the EU. BioArcticAB nordiclifescience.org/eu-approves-le…

"The EU has a choice to make. Either we act and secure Europe’s position as a leading region for research and innovation, or we watch as others take the lead," says Sofia Wallström, CEO Lif Sverige nordiclifescience.org/joint-swedish-…

The Board Biotage has decided to recommend that Biotage shareholders accept the offer. KKR nordiclifescience.org/kkr-makes-sek-…

"To be able to control costs and serve patients, the world will need biosimilars," says Róbert Wessman, Icelandic businessman and entrepreneur Alvotech nordiclifescience.org/global-health-…

"We are interested in identifying new targets for interventions that could then be used to develop new drugs and vaccines or help us understand why some mosquito species transmit malaria while others do not." Umeå universitet #WorldMalariaDay2025 nordiclifescience.org/world-malaria-…

"We are pleased with the CHMP’s positive recommendation for market authorization for Oczyesa octreotide monthly depot for the treatment of acromegaly," says Fredrik Tiberg, Camurus nordiclifescience.org/chmp-recommend…